Please assess the completion status of the following clinical trial:

Trial Title: Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent~2. Diagnosed with advanced NSCLC (phase IIIB/IV) through pathology, with measurable nidus(using RECIST 1.1)~3. at least two systematic chemotherapy with upwards of 3-line treatments or cannot suffer~4. Patients must provide detectable specimen (from tumor tissue or hydrothorax) before participating, who negative in EGFR\&ALK can participate or who positive in EGFR\&ALK, have or have not drug tolerance after the treatment with relative targeted drugs~5. ECOG PS：0-1,Expected Survival Time: Over 3 months~6. main organs function is normal~7. The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it~Exclusion Criteria:~1. have used Anlotinib before~2. Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)~3. examined as positive in EGFR\&ALK mutation detection and never take the treatment of TKIs~4. central lung squamous carcinoma along with cavum, or non-small cell lung cancer along with hemoptysis (\>50ml/day)~5. other kinds of malignancies within 5 years or for now~6. plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks before taking the treatment with experimental drug); The patients who have already taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping~7. have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included~8. with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus)~9. pleural effusion or ascites, resulting in respiratory syndrome (≥CTC AE level 2)~10. symptoms of brain metastases cannot be controlled and treated within less than 2 months~11. get any severe diseases or the ones that cannot be controlled~12. take major surgical treatments, open biopsy, or get overt traumatic injury within 28 days before grouping~13. have any habitus or medical history of hemorrhage, however severe it is; the patients who have non healing wounds, ulcer or fracture after any events with hemorrhage or bleeding (≥CTCAE level 3)~14. get arterial/venous thrombosis within 6 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism~15. ever abuse psychiatric drugs and cannot abstain or who are diagnosed with mental disorder~16. have participated in other clinical trials of anti-tumor medicine within 4 weeks~17. diagnosed with disease which will severely endanger the security of patients or influence the completion of this research.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Anlotinib (Type: EXPERIMENTAL): Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
- Placebo (Type: PLACEBO_COMPARATOR): Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent

Based on this trial design, predict the completion outcome and termination type (if applicable).